Approximately 70% of all recently approved biopharmaceuticals were recombinant proteins expressed from mammalian cell lines. In turn, the need for more stable, scalable, and high-titer cell lines is on the rise. With the global cell line development (CLD) market estimated to grow to more than $9.8 billion (CAGR ~12.5%), this demand shows no signs of slowing down. More and more companies and institutions are looking for ways to streamline and expedite the CLD process to meet market demand.
Download this content collection to learn:
Complete the Form to Download
Watch this webinar to learn how the iQue®3, Octet® and Ambr® 15 CC platforms, combined with Sartorius expertise, can help streamline early cell line development with an integrated solution that is data-driven at every step.
Watch Now
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.